The Risk Delayed gastric emptying from GLP-1 drugs is associated with increased aspiration risk and increased postoperative pulmonary morbidity
If you are referred for medically necessary treatment (such as a biologic infusion) we coordinate with your specialist, follow medication specific safety protocols, and monitor you during and after your visit
The TRANSCEND Phase 3 trials are specifically studying Retatrutide in type 2 diabetes populations and are expected to report results in 2026
Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, et al
Independent literature is thin
However, its crucial to remember that using semaglutide GLP-1 to lose weight is dependent on your initial weight, lifestyle, diet, and the dose of the drug